TrialLancet (London, England)2018

Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.

J Michael Gaziano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.